The prevalence and disease burden of cardiovascular disease (CVD) and the widespread use of medications for its prevention and treatment have led to the concept that a single pill containing several cardiovascular medications, a “polypill,” might be useful in more effectively delivering pharmacologic interventions than the same medications prescribed and taken separately. For about a decade and a half there have been active discussions of combination pills for primary or secondary prevention of CVD.1 The discussion is consistent with the widespread interest in the importance of noncommunicable diseases, particularly in low- and middle-income countries.
Gaziano JM. Progress With the Polypill? JAMA. 2013;310(9):910–911. doi:10.1001/jama.2013.277066
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: